Australian biopharmaceutical company Telix Pharmaceuticals Limited (ASX:TLX) announced on Wednesday that it is collaborating on the production of the alpha-emitting isotope, actinium-225 (225Ac), with Berlin-based Eckert & Ziegler SE (EZAG) (ETR:EUZ), a specialist in isotope-related components for nuclear medicine and radiation therapy.

This partnership will provide Telix with additional access to 225Ac, a crucial element for developing targeted alpha therapies (TATs).

By combining EZAG's cyclotron-based technology with Telix's global manufacturing capabilities, the two companies aim to increase the production of 225Ac, accelerating the development of Telix's alpha therapy candidates and meeting future commercial demand.

Alpha emitters like 225Ac offer a promising approach to cancer treatment, as they can deliver highly targeted radiation to tumors while minimising damage to healthy tissues. This collaboration between Telix and Eckert & Ziegler highlights the growing importance of alpha therapy in the field of radiopharmaceuticals.